StockData

Vanda Pharmaceuticals Inc. (VNDA) stock

VNDANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3056% below fair value
$3.67−0.08 (-2.13%)

Close on Nov 19, 2026Market cap $221.92MP/E –Yield –

Vanda Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Vanda Pharmaceuticals's operating income for the twelve months ending Sep 30, 2026 was -$177.91M. For fiscal 2025 it was -$151.17M. The highest annual figure on record is $42.17M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$151.17M–
FY2024Dec 31, 2024-$40.66M–
FY2023Dec 31, 2023-$13.95M-320.4%
FY2022Dec 31, 2022$6.33M-85.0%
FY2021Dec 31, 2021$42.17M+54.8%
FY2020Dec 31, 2020$27.24M+19.4%
FY2019Dec 31, 2019$22.81M+4.9%
FY2018Dec 31, 2018$21.74M–
FY2017Dec 31, 2017-$16.90M–
FY2016Dec 31, 2016-$18.57M–
FY2015Dec 31, 2015-$40.19M-300.3%
FY2014Dec 31, 2014$20.06M–
FY2013Dec 31, 2013-$21.20M–
FY2012Dec 31, 2012-$29.18M–
FY2011Dec 31, 2011-$10.71M-221.1%
FY2010Dec 31, 2010$8.84M–
FY2009Dec 31, 2009-$35.95M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$23.52M–
Q2 FY2026Jun 30, 2026-$63.81M–
Q1 FY2026Mar 31, 2026-$50.22M–
Q4 FY2025Dec 31, 2025-$40.35M–
Q3 FY2025Sep 30, 2025-$31.28M–
Q2 FY2025Jun 30, 2025-$38.50M–
Q1 FY2025Mar 31, 2025-$41.03M–
Q4 FY2024Dec 31, 2024-$10.28M–
Q3 FY2024Sep 30, 2024-$11.00M–
Q2 FY2024Jun 30, 2024-$10.15M–
Q1 FY2024Mar 31, 2024-$9.24M-560.8%
Q4 FY2023Dec 31, 2023-$7.09M-207.0%
Q3 FY2023Sep 30, 2023-$6.00M-253.4%
Q2 FY2023Jun 30, 2023-$2.87M-182.8%
Q1 FY2023Mar 31, 2023$2.00M–
Q4 FY2022Dec 31, 2022$6.63M-23.2%
Q3 FY2022Sep 30, 2022$3.91M-63.9%
Q2 FY2022Jun 30, 2022$3.46M-72.0%
Q1 FY2022Mar 31, 2022-$7.67M-174.2%
Q4 FY2021Dec 31, 2021$8.64M-17.4%
Q3 FY2021Sep 30, 2021$10.82M+39.7%
Q2 FY2021Jun 30, 2021$12.37M+34.9%
Q1 FY2021Mar 31, 2021$10.34M–
Q4 FY2020Dec 31, 2020$10.45M+146.3%
Q3 FY2020Sep 30, 2020$7.74M-28.0%
Q2 FY2020Jun 30, 2020$9.17M-7.3%
Q1 FY2020Mar 31, 2020-$125.00K–
Q4 FY2019Dec 31, 2019$4.24M-53.6%
Q3 FY2019Sep 30, 2019$10.76M+72.6%
Q2 FY2019Jun 30, 2019$9.90M+152.9%
Q1 FY2019Mar 31, 2019-$2.09M-185.5%
Q4 FY2018Dec 31, 2018$9.15M–
Q3 FY2018Sep 30, 2018$6.23M–
Q2 FY2018Jun 30, 2018$3.91M–
Q1 FY2018Mar 31, 2018$2.44M–
Q4 FY2017Dec 31, 2017-$2.15M–
Q3 FY2017Sep 30, 2017-$4.92M–
Q2 FY2017Jun 30, 2017-$1.92M–
Q1 FY2017Mar 31, 2017-$7.91M–
Q4 FY2016Dec 31, 2016-$654.00K–

More Vanda Pharmaceuticals figures

See a number that looks wrong?